Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation

References

• Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118:1340–1347.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Freedman B, de Caterina R, et al. Stroke prevention in atrial fibrillation: past, present and future comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117:1230–1239.
   PubMed Web of Science ®Google Scholar
• Franchini M, Liumbruno GM, Bonfanti C, et al. The evolution of anticoagulant therapy. Blood Transfus. 2016;14:175–184.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451:914–918.
   PubMed Web of Science ®Google Scholar
• Smith M, Wakam G, Wakefield T, et al. New trends in anticoagulation therapy. Surg Clin North Am. 2018;98:219–238.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest. 2010;137:263–272.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost. 2017;117:1283–1288.
   PubMed Web of Science ®Google Scholar
• Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal use of oral anticoagulants in atrial fibrillation: has the introduction of direct oral anticoagulants improved prescribing practices? Am J Cardiovasc Drugs. 2016;16:183–200.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393.
   Google Scholar
• Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57:1339–1348.
   PubMed Web of Science ®Google Scholar
• Furie B, Furie BC. In vivo thrombus formation. J Thromb Haemost. 2007;5:12–17.
   PubMed Web of Science ®Google Scholar
• Gailani D, Gruber A. Factor XI as a therapeutic target. Arterioscler Thromb Vasc Biol. 2016;36:1316–1322.
   PubMed Web of Science ®Google Scholar
• Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10:136–144.
   PubMed Web of Science ®Google Scholar
• Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci. 2007;104:6388–6393.
   PubMed Web of Science ®Google Scholar
• Gould TJ, Vu TT, Swystun LL, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. 2014;34:1977–1984.
   PubMed Web of Science ®Google Scholar
• McFadyen JD, Jackson SP. Differentiating haemostasis from thrombosis for therapeutic benefit. Thromb Haemost. 2013;110:859–867.
   PubMed Web of Science ®Google Scholar
• Smith SA, Gajsiewicz JM, Morrissey JH. Ability of polyphosphate and nucleic acids to trigger blood clotting: some observations and caveats. Front Med. 2018.
   Web of Science ®Google Scholar
• He R, Chen D, He S. Factor XI: hemostasis, thrombosis, and antithrombosis. Thromb Res. 2012;129:541–550.
   PubMed Web of Science ®Google Scholar
• Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202:271–281.
   PubMed Web of Science ®Google Scholar
• Renné T, Oschatz C, Seifert S, et al. Factor XI deficiency in animal models. J Thromb Haemost. 2009;7:79–83.
   PubMed Web of Science ®Google Scholar
• Key NS. Epidemiologic and clinical data linking factors XI and XII to thrombosis. Hematology. 2014;2014:66–70.
   PubMedGoogle Scholar
• Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia. 2006;12:490–493.
   PubMed Web of Science ®Google Scholar
• Seligsohn U. Factor {XI} deficiency in humans. J Thromb Haemost JTH. 2009;7(Suppl 1):84–87.
   PubMed Web of Science ®Google Scholar
• Gailani D, Bane CE, Gruber A. Factor XI and contact activation as targets for antithrombotic therapy. J Thromb Haemost. 2015;13:1383–1395.
   PubMed Web of Science ®Google Scholar
• Renné T, Schmaier AH, Nickel KF, et al. In vivo roles of factor XII. Blood. 2012;120:4296–4303.
   PubMed Web of Science ®Google Scholar
• Van Montfoort ML, Meijers JCM. Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. Hematology. 2014;2014:60–65.
   PubMedGoogle Scholar
• Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232–240.
   Web of Science ®Google Scholar
• Bickmann JK, Baglin T, Meijers JCM, et al. Novel targets for anticoagulants lacking bleeding risk. Curr Opin Hematol. 2017;24:419–426.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, García-Fuentes M, Suárez-Gea ML. Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017;12:1195–1205.
   PubMed Web of Science ®Google Scholar
• Crosby JR, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor xi oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol. 2013;33:1670–1678.
   PubMed Web of Science ®Google Scholar
• Younis HS, Crosby J, Huh JI, et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood. 2012;119:2401–2408.
   PubMed Web of Science ®Google Scholar
• Liu Q, Bethune C, Dessouki E, et al. ISIS-fxirx, a novel and specific antisense inhibitor of factor xi, caused significant reduction in fxi antigen and activity and increased aptt without causing bleeding in healthy volunteers. ASH Annu Meet Abstr. 2011;118:209.
   Google Scholar
• Buller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372:232–240.
   PubMed Web of Science ®Google Scholar
• Geng X, Kong X, Hu H, et al. Research and development of therapeutic mAbs: an analysis based on pipeline projects. Hum Vaccines Immunother. 2015.
   Web of Science ®Google Scholar
• Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116:3981–3989.
   PubMed Web of Science ®Google Scholar
• Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113:936–944.
   PubMed Web of Science ®Google Scholar
• Gailani D, Smith SB. Structural and functional features of factor XI. J Thromb Haemost. 2009;7:75–78.
   PubMed Web of Science ®Google Scholar
• Schumacher WA, Seiler SE, Steinbacher TE, et al. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol. 2007;570:167–174.
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Watson CA, et al. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis. 2011.
   Web of Science ®Google Scholar
• Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost. 2010;104:302–310.
   PubMed Web of Science ®Google Scholar
• Hangeland JJ, Friends TJ, Rossi KA, et al. Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity. J Med Chem. 2014;57:9915–9932.
   PubMed Web of Science ®Google Scholar
• Deng H, Bannister TD, Jin L, et al. Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an α-ketothiazole arginine. Bioorganic Med Chem Lett. 2006;16:3049–3054.
   PubMed Web of Science ®Google Scholar
• Quan ML, Wong PC, Wang C, et al. Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors. J Med Chem. 2014;57:955–969.
   PubMedGoogle Scholar
• Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123:2102–2107.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, García-Fuentes M, Suárez-Gea ML, et al. Factors XI and XII as targets for new anticoagulants. Front Med. 2017;4:147–154.
   Web of Science ®Google Scholar